Elevation Oncology Inc Aktie News

Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected mid-Q3 of 2024; Additional data expected 1st half of 2025. HER3-ADC is another ADC being developed in the pipeline for the treatment of patients with HER3-expressning solid tumors; It has been shown that up to 42% of tumors express HER3. Nomination of ADC candidate for HER3-ADC clinica...

-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-track to nominate development candidate in 2H 2024 -- -- Raised $44.2 million year-to-date through ATM facility, exte...

Elevation Oncology, Inc. has had a successful year, transitioning from the shelving of their seribantumab program to focusing on antibody-drug conjugates. Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promising early results. Elevation Oncology is also exploring anti-HER3 ADCs and is close to nominating a candidate for clinical development in this area.

-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for ...

Personalized health screening from a “smart toilet”

--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 -- -- Preclinical proof-of-concept data for HER3-ADC program to be presented at AACR Annual Meeting; plan to nominate development candidate in 2024 – -- Raised approximately $17.0M in net proceeds through at-the-market (ATM...

Recently, I watched portions of a YouTube video that tangentially but importantly related to overbought stocks to sell. An options trader boasted about an 80% success rate with his system, which sounded like nonsense.

-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tum...